




RealRate

PHARMACEUTICAL 2022

Rain Oncology Inc
Rank 129 of 471



RealRate

The First AI Rating Agency

www.realrate.ai



PHARMACEUTICAL 2022

Rain Oncology Inc
Rank 129 of 471

The relative strengths and weaknesses of Rain Oncology Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Rain Oncology Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 103% points. The greatest weakness of Rain Oncology Inc is the variable Research and Development, reducing the Economic Capital Ratio by 12% points.

The company's Economic Capital Ratio, given in the ranking table, is 358%, being 83% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	146,146
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,315
Liabilities, Non-Current	321
Other Assets	829
Other Compr. Net Income	-89
Other Expenses	2.0
Other Liabilities	0
Other Net Income	120
Other Revenues	0
Property and Equipment	165
Research and Development	40,773
Selling, General and Administrative Expense	10,739

Output Variable	Value in 1000 USD
Assets	147,140
Liabilities	16,636
Expenses	51,514
Revenues	0
Stockholders Equity	130,504
Net Income	-51,394
Comprehensive Net Income	-51,438
BaseVar	107,750
ECR before LimitedLiability	285%
Economic Capital Ratio	358%